经皮微波凝固联合肝动脉化疗栓塞治疗少血供型肝癌  

Percutaneous Microwave Coagulation Therapy with Transcatheter Arterial Chemoembolization for Hypovascular Liver Cancer

作　　者：沈杰[1] 马爱英[1] 王海洁[1] 王亚进[1] 刘秋如[1] 

机构地区：[1]解放军第455医院肿瘤科,上海200052

出　　处：《中国临床医学》2007年第2期188-190,共3页Chinese Journal of Clinical Medicine

摘　　要：目的:探讨经皮微波凝固(PMCT)联合肝动脉化疗栓塞(TACE)治疗少血供型肝癌的疗效。方法:62例经组织学和数字减影血管造影(DSA)证实为少血供型的肝细胞肝癌9例、肝内胆管细胞癌25例、转移性肝癌28例,共113个目标病灶。分为两个治疗组:(1)联合组32例,先行TACE,再行超声引下PMCT,根据治疗后肿瘤的坏死和复发情况,决定是否重复PMCT或TACE;(2)对照组30例,仅行TACE。结果:经治疗后,联合组和对照组患者受益率分别为90．6％和53．3％,1年生存率、2年生存率分别为90．6％、59．4％和40％、3．3％,血清肿瘤指标转阴率分别为76．7％和17．9％,两组间比较均有显著差异(P< 0．01)。结论:PMCT联合TACE治疗少血供型肝癌是一种安全、有效、微创的方法。Objective：To investigate the efficacy of percutaneous microwave coagulation therapy （PMCT） combined with transcatheter hepatic arterial chemoembolization（TACE） in treating hypovascular liver cancer. Methods： A total of 113 nodules of hypovascular liver cancer in 62 patients were diagnosed by liver biopsy and digital subtraction angiography（DSA）. Of the 62 patients, 9 cases were with hepatocellular carcinoma, 25 cases with cholangiocarcinoma and 28 cases with metastatic liver tumor. The patients were divided into two groups： （1）In group TACE, 30 cases were treated with TACE. （2） In group TACE ＋ PMCT, 32 cases were treated with TACE and then followed by ultrasound-guided PMCT. If tumor necrosis was not complete or recurrence was detected, repeated PMCT or TACE was performed. Results： After treatments, patients response rates was 90.6% and 53.3%, 1-year and 2-year survival rates was 90.6%, 59.4% and 40%, 3.3%, the rate of normalized serum tumor maker was 76. 7% and 17.9%, respectively. There were significant statistical differences between two groups（P〈 0.01）. Conclusion： The combination of PMCT and TACE therapy for hypovascular liver cancer is a safe, effective and mini-trauma modality.

关 键 词：少血供肝肿瘤 微波凝固 肝动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤]